Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-09-06
2005-09-06
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S090000
Reexamination Certificate
active
06939877
ABSTRACT:
Compounds of the Formula:are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
REFERENCES:
patent: 5276042 (1994-01-01), Crenshaw et al.
patent: 5811436 (1998-09-01), Leonard et al.
patent: 6218405 (2001-04-01), Birch et al.
patent: 6599915 (2003-07-01), Tran et al.
patent: 0 151 826 (1985-08-01), None
patent: 0 542 136 (1993-05-01), None
patent: 2 103 639 (1972-04-01), None
patent: 1354554 (1974-06-01), None
patent: 91/13872 (1991-09-01), None
patent: WO 92/09281 (1992-06-01), None
patent: 94/01437 (1994-01-01), None
patent: 95/07274 (1995-03-01), None
patent: 98/16530 (1998-04-01), None
patent: 98/40386 (1998-09-01), None
Birch, A. M. et al., “N-Substituted (2,3-Dihydro-1,4-benzodioxin-2-yl)methylamine Derivatives as D2Antagonists/5-HT1APartial Agonists with Potential as Atypical Antipsychotic Agents,”J Med Chem,1999, 42, 3342-3355.
Artigas, F., et al., “Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors,”Arch Gen Psychiatry,Mar. 1994, 51, 248-251.
Blier, P., et al., “Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression,”J. of Clinical Psychopharmacology,1995, 15(3), 217-222.
Bundgaard, (Ed.), Design of Prodrugs,Elsevier,1985.
Bundgaard, H., “Means to enhance penetration; Prodrugs as a means to improve the delivery of peptide drugs,”Advanced Drug Deliver Reviews,1992, 8, 1-38.
Bundgaard,J. of Pharmaceutical Sciences,1988, 7(285 et seq.).
Cheetham, S.C., et al., “[3H]paroxetine binding in rat frontal cortex strongly correlates with[3H]5-HT uptake: effect of administration of various antidepressant treatments,”Neuropharmacol.,1993, 32(8), 737-743.
Eliel, E.L., Stereochemistry of Carbon Compounds,McGraw-Hill, NY,1962.
Higuchi, et al. (Eds.), Prodrugs as Novel Drug Delivery Systems,American Chemical Society,1975.
Jacques, et al., Enantiomers, Racemates and Resolutions,Wiley Interscience, NY,1981.
Krogsgaard-Larsen, et al. (Eds.), “Design and Application of Prodrugs,”Textbook of Drug Design and Development,1991, Chap. 5, 113-191.
Lazareno, S., et al., “Pharmacological characterization of acetylcholine-stimulated [3S]-GTPγS binding mediated by human muscarinic m1-m4 receptors: antagonist studies,”Br. J. Pharmacol.,1993, 109, 1120-1127.
Ostrowski, S., “A synthesis of fused pyrimidine mono-n-oxides,” Heterocycles, 1996, 43(2), p. 389-396.
Perez, V., et al., “Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment,”The Lancet,m May 31, 1997, 349, 1594-1597.
Remington's Pharmaceutical Sciences, 17thEd., Gennaro, A.R. (Ed.),Mack Publishing Company,Easton, PA, 1985.
Tome, M.B., et al., “Serotonergic autoreceptor blocade in the reduction of antidepressant latency: personality variables and response to paroxetine and pindolol,”J. Affect Disord,1997, 44, 101-109.
Tome, M.B., et al., “Paroxetine and pindolol: a randomized trial of serotonergic antoreceptor blockade in the reduction of antidepressant latency,”Int. Clin. Psychopharmacol,1997, 12, 81-89.
Widder, et al. (Eds.), Methods in Enzymology,Academic Press,1985, vol. 4.
Wilen, S.H., “Tables of Resolving Agents and Optical Resolutions,”Univ. of Notre Dame Press,Notre Dame, IN, E.L. Eliel (Ed.), 1972, p. 268-298.
Wilen, S.H., et al., “Strategies in optical resolutions,”Tetrahedron,1977, 33, 2725-2736.
Asselin Magda
Evrard Deborah A.
Stack Gary Paul
Webb Michael Bryon
Chang Celia
Woodcock & Washburn LLP
Wyeth
LandOfFree
Antidepressant piperidine derivatives of heterocycle-fused... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antidepressant piperidine derivatives of heterocycle-fused..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antidepressant piperidine derivatives of heterocycle-fused... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3410049